Publications
Healthcare
Insights
In our most recent case studies, market research reports, conference talks, and other publications, we share and visualize our market insights.
Publications
In our most recent case studies, market research reports, conference talks, and other publications, we share and visualize our market insights.
With our expertise in DiGA approval and our international network, we support our customers in all issues related to the PECAN process.
In an extensive article in PM-Report, Germany’s most significant pharma magazine, Digital Oxygen’s experts provide a 360° overview of DiGA in the context of pharma.
Our clients have a plethora of options when it comes to engaging with digital health providers.
The Advanced Diabetes Technology Landscape 2023 is an extensive overview of companies shaping the future of diabetes care.
There are high hopes that 6G will revolutionize digital health. Axel Meiling provides insights why 6G per se won’t be the solution – and what the actual blockers for digital health are.
One aspect of DiGA is frequently left out in recent reports: The unknown number of DiGA prescriptions – the part of the DiGA iceberg that is not visible.
At the panel discussion at this year’s Med-Tech World in Malta, the question was discussed: Does digitalization succeed in creating health equality?
With the DiPA Canvas, Digital Oxygen provides a straight-forward tool for the self-assessment of essential questions for any DiPA manufacturer.
The DiGA Canvas is a comprehensive tool to assess the crucial questions, challenges, and requirements for your DiGA.
In this article, Torsten Christann comments on the importance, opportunities, and downsides of data for the pharma industry’s future business models.
The Advanced Diabetes Technology Landscape 2022 gives a structured overview of the companies shaping the future of Diabetes Care.
There is a trend of DiGA start-ups looking for corporate partners and vice versa. But why?
Our case study and framework showcases the relevant dimensions and questions to be asked when considering a DiGA acquisition.
Sensors, wearables, apps: Torsten Christann comments on the opportunities of self-measurement for the generation of Real-World-Evidence in Market Access processes.
In this article, Torsten Christann addresses the question whether pharma corporations should add DiGA to their portfolio or no.
At WIG2 Digital Health Conference, Healthcare Expert Alexander Voigt talked about what matters after the regulatory market access: Reaching patients.
This study examines the pain points and inefficiencies of diabetes care in German hospitals – and how there is a case for Glucometry MedTechs to disrupt the industry.
Clients and Partners